Publications

Publications

Filter Results: (52) Arrow Down

Show Results For

← Page 2 of 52 Results →
  • 2013
  • Working Paper

Visualizing and Measuring Enterprise Architecture: An Exploratory BioPharma Case

By: Robert Lagerstrom, Carliss Baldwin, Alan MacCormack and David Dreyfus
We test a method that was designed and used previously to reveal the hidden internal architectural structure of software systems. The focus of this paper is to test if it can also uncover new facts about the components and their relationships in an enterprise... View Details
Keywords: Complexity; Applications and Software; Product Design; Pharmaceutical Industry
Related
  • September 2022
  • Article

Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities

By: Leemore Dafny, Christopher Ody and Teresa Rokos
The federal Anti-Kickback Statute prohibits biopharmaceutical manufacturers from directly covering Medicare enrollees’ out-of-pocket spending for the drugs they manufacture, but manufacturers may donate to independent patient assistance charities and earmark donations... View Details
Keywords: Cost Sharing; Prescription Drugs; Drug Spending; Medicare; Dual Eligibility; Cost; Health Care and Treatment; Philanthropy and Charitable Giving; Pharmaceutical Industry
Related
  • 27 Sep 2011
  • First Look

First Look: September 27

terms expire, changes to the U.S. healthcare system are also of significance to patients and the pharmaceutical industry internationally. This article evaluates how the ACA will affect the size of the View Details
Keywords: Sean Silverthorne
  • 2010
  • Working Paper

Boundary Spanning in a For-profit Research Lab: An Exploration of the Interface Between Commerce and Academe

By: Christopher C. Liu and Toby E. Stuart
In innovative industries, private-sector companies increasingly are participants in open communities of science and technology. To participate in the system of exchange in such communities, firms often publicly disclose what would otherwise remain private discoveries.... View Details
Keywords: For-Profit Firms; Higher Education; Information Publishing; Innovation and Invention; Science-Based Business; Social and Collaborative Networks; Boundaries; Biotechnology Industry; Biotechnology Industry
Related
  • August 2023
  • Case

Constellation Pharmaceuticals: Corporate Development at a Novel Therapeutic Company

By: Satish Tadikonda and Brad Prosek
Constellation Pharmaceuticals was a company focused on epigenetic therapies for cancer patients. Despite a promising start and an early deal with a leading biopharma company, the company weathered twin setbacks in the end of a major research collaboration and the... View Details
Keywords: Mergers and Acquisitions; Health Care and Treatment; Organizational Change and Adaptation; Research and Development; Business Strategy; Partners and Partnerships; Goals and Objectives; Pharmaceutical Industry; United States
Related
  • Web

Faculty & Advisors | MBA

Centerview in 2009, the firm has been a leading advisor to the global Biopharmaceutical industry most notable representing biotechnology companies on strategic defense. In the period from 2019 to 2021,... View Details
  • Web

Sample Student Projects - Institute For Strategy And Competitiveness

Automotive Cluster (2012) Tirupur (India) Knitwear (2011) India (Maharashtra) Automotive Cluster (2010) Maharashtra Biopharmaceutical Cluster (2009) Bangalore Biotechnology (2008) Gujarat Diamonds (2008) Bollywood — Maharashtra and... View Details
  • Web

Academics - Health Care

interests in organizations that provide health care (e.g., hospitals, medical groups, retail clinics) or in firms that partner with, supply, consult to, or invest in such organizations (e.g., payers, biopharmaceutical and device... View Details
  • 09 Mar 2023
  • Blog Post

African American Student Union Spotlight on Joint Degrees

before and during the MBA program. Chris Egi (JD/MBA 2026) Where is your hometown? My hometown is Markham, Ontario, Canada, a suburb of the Greater Toronto Area. What was your pre-MBA industry and role? Before HBS, I was an investment... View Details
  • 27 Mar 2012
  • First Look

First Look: March 27

Corp. (B) Regina E. Herzlinger and Natalie KindredHarvard Business School Supplement 311-087 This case, the denouement to "PAREXEL International Corp. (A)," describes developments at PAREXEL and the biopharmaceutical View Details
Keywords: Carmen Nobel
  • Fast Answer

R&D expenditures: Companies

-  R&D Activity Data series European Commission - Economics of Industrial Research and Innovation R&D Monitor See also (in print): Research & Development Growth Trends  In print: Ref T176 .R25  in... View Details
  • 22 Jul 2014
  • First Look

First Look: July 22

Corporate Finance Attracting Long-Term Investors Through Integrated Thinking and Reporting: A Clinical Study of a Biopharmaceutical Company By: Knauer, Andrew, and George Serafeim Abstract—Faced with a large percentage of investors that... View Details
Keywords: Sean Silverthorne
  • 13 Oct 2016
  • News

Adding Muscle to the Fight Against Disease

If you are one of the 17 million people who participated in the Ice Bucket Challenge a couple of summers ago, the money you helped raise to support ALS research may be at work today in a late-stage biopharmaceutical company headed by... View Details
Keywords: Deborah Blagg
  • 24 Jun 2008
  • First Look

First Look: June 24, 2008

Patenting on the Rate, Quality, and Direction of (Public) Research Output Authors: Pierre Azoulay, Waverly Ding, and Toby E. Stuart Periodical: Journal of Industrial Economics (forthcoming) Abstract We examine the influence of faculty... View Details
Keywords: Martha Lagace
  • 28 Jul 2015
  • First Look

First Look: July 28, 2015

country-level factors that limit firms' use of selective disclosure by intensifying scrutiny on them and by diffusing global norms to their headquarters countries. We test our hypotheses using a novel panel dataset of 4,750 public companies across many View Details
Keywords: Carmen Nobel
  • 11 May 2010
  • First Look

First Look: May 11

this case:http://cb.hbsp.harvard.edu/cb/product/610031-PDF-ENG Revitalizing Dell Jan W. RivkinHarvard Business School Case 710-442 Dell Inc., with its vaunted Direct Model, defined success in the personal computer industry for more than a... View Details
Keywords: Martha Lagace
  • 22 Aug 2006
  • First Look

First Look: August 22, 2006

is a need for a fund like this at the time of the case. Supports discussion of specialized versus generalized venture capital funds. Purchase this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=805075 John Moran and the Orthopedics View Details
Keywords: Martha Lagace
  • 01 May 2007
  • First Look

First Look: May 1, 2007

possibility that the effects of FDI differ by sector. Second, we differentiate FDI based on objective qualitative industry characteristics including the average skill intensity and reliance on external capital. Third, we use a new dataset... View Details
Keywords: Sean Silverthorne
  • 18 Mar 2014
  • First Look

First Look: March 18

the ratings. Our tests examine whether these forms of disclosure reflect firms' real efforts to combat corruption or are cheap talk. We find that the ratings are related to enforcement and monitoring, country and industry corruption risk,... View Details
Keywords: Sean Silverthorne
  • 07 Feb 2017
  • First Look

First Look at New Research: February 7

2017 New York: Oxford University Press Managing Risk in Reinsurance: From City Fires to Global Warming By: Hauter, Niels Viggo, and Geoffrey Jones, eds. Abstract—This is the first book to provide a comprehensive history of the reinsurance View Details
Keywords: Sean Silverthorne